Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeneFIX PK Study in Chinese Hemophilia B Subjects
NCT02213250Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2015
- Primary completion
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 96 hours, Area Under the Concentration Time Curve From Time 0 to Last Quantifiable Concentration at 96 hours and 8 more. Started Mar 2015; status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT02213250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213250.